Temperature-Optimized Bacillus Strains Patent Grant

The USPTO granted patent US12593849B2 to Chr. Hansen A/S on April 7, 2026, covering new strains of Bacillus paralicheniformis with improved growth rates and plant growth promoting properties. The patent names six inventors including Patricia Dominguez Cuevas and Lars Moelbak, with 21 claims. Filing date was August 28, 2020, under application number 17638152.

Virus-like Particles Patent Granted to University of Denver

The USPTO granted Patent US12594329B2 to the University of Denver on April 7, 2026. The patent covers virus-like particles, compositions, antibody detection tests using virus-like particles, and methods of producing non-replicating virus-like particles from modified viral genomes. Schuyler B. van Engelenburg is the sole inventor of the 9-claim patent.

CD8-specific capture agents, compositions, and methods of using and making

The USPTO granted Regeneron Pharmaceuticals patent US12594350B2 covering stable peptide-based CD8 capture agents for use as detection agents. The patent was issued April 7, 2026, naming Regeneron Pharmaceuticals, Inc. as assignee and Heather Dawn Agnew and Bert Tsunyin Lai as inventors. The application, filed April 4, 2017 (Application No. 15478596), contains 13 claims.

HIV Oral Drug Composition Patent

The USPTO granted Patent US12594244B2 to Gilead Sciences, Inc. covering a solid oral dosage form combining tenofovir alafenamide, emtricitabine, and a compound of Formula I for HIV treatment. The patent contains 29 claims and was granted on April 7, 2026, with a filing date of September 29, 2025.

Topiramate oral liquid suspension patent granted

USPTO granted patent US12594241B2 to inventors Paul Sudhakar and Scott Boyer for an oral liquid suspension formulation containing topiramate (Application No. 18462651). The patent contains 29 claims covering the composition and methods of medical treatment using the formulation. Generic and branded pharmaceutical manufacturers should assess this patent for potential freedom-to-operate implications.

Exosome Production Method for Cancer Therapeutic Delivery

USPTO granted patent US12594344B2 to China Medical University for a large-scale exosome production method using cyclic tensile bioreactors. The patent covers exosomes with anti-HLA-G protein configured as delivery vehicles for cancer therapeutic agents. The grant includes 10 claims and applies to A61P 35/00 (antineoplastic agents) and related CPC classifications.

Nanoparticulate drug delivery for therapeutic applications

The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.

Cisplatin-Eugenol Analogue for Cancer Treatment

The USPTO granted Patent US12594338B2 to King Faisal Specialist Hospital & Research Centre for a cisplatin-eugenol compound with anti-cancer properties. The patent covers the compound composition, synthesis method, pharmaceutical formulations, and methods of cancer treatment. Inventors include Abdelilah Aboussekhra, Ibrahim Al-Jammaz, Basem Al-Otaibi, and Noura N. Alraouji. The patent was filed on July 27, 2023.

Probiotics to prevent cognitive dysfunction

USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.

Mesembrine Crystalline Salt Patent Grant

USPTO granted Patent US12595231B2 to Kanna Health Ltd covering novel crystalline salt forms of mesembrine, specifically mesembrine besylate salt. The patent, filed under Application No. 18614136 with 18 claims, covers the chemical compound (C17H23NO3) and its use as a medicament.